Acetazolamide Challenge With Perfusion in the Prediction of Cerebral Vasospasm

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators propose a technique using cone beam CT perfusion (CBCTP) imaging with an acetazolamide challenge as a potential diagnostic tool to detect a defect in cerebral autoregulation at a time when it has not yet caused clinically apparent signs or symptoms. 30 participants will be enrolled at the University of Wisconsin - Madison and can expect to be on study for about 2 weeks.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Wisconsin, Madison
• Treatments: Acetazolamide

Criteria

Inclusion Criteria:

• Patients with aneurysmal subarachnoid hemorrhage presenting to our institution within 24 hours of symptom onset

• Adults, 18 years of age or older

• Women of childbearing potential must not be pregnant (negative urine pregnancy test)

Exclusion Criteria:

• Contraindication to acetazolamide (i.e. sulfonamide allergy, renal or liver failure)

• Contraindication to contrast media (Allergy or abnormal serum Cr and/or GFR based on current UW guidelines for IV contrast)

• Renal insufficiency, history of renal failure or renal transplant

• Hunt and Hess grade 1 and 5 (Attached protocol provides details on the grading scale. Grade 1 have lowest yield for vasospasm and Grade 5 are by definition critically ill and unstable patients)

• Critically ill patients who are unstable and who cannot undergo scans within the proposed timeline i.e. within 24 hours of the onset of their symptoms.